Showing results (91-100 of 121) with videos related to
Sort By:
Pageof 13
American Heart Journal|September 15, 2019
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trialKausik K Ray, Stephen J Nicholls, Henry D Ginsberg, et al.Atherosclerosis|February 13, 2016
RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular diseaseDean Gilham, Sylwia Wasiak, Laura M Tsujikawa, et al.Journal of the American Academy of Child and Adolescent Psychiatry|December 1, 2006
Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS)Betsy Kennard, Susan Silva, Benedetto Vitiello, et al.Cardiovascular Diabetology|January 8, 2021
Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE studyStephen J Nicholls, Gregory G Schwartz, Kevin A Buhr, et al.Data in Brief|August 30, 2016
Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytesSylwia Wasiak, Dean Gilham, Laura M Tsujikawa, et al.Atherosclerosis|November 27, 2018
Apabetalone downregulates factors and pathways associated with vascular calcificationDean Gilham, Laura M Tsujikawa, Christopher D Sarsons, et al.American Heart Journal|December 18, 2007
Role of magnetic resonance imaging in arrhythmogenic right ventricular dysplasia: insights from the North American arrhythmogenic right ventricular dysplasia (ARVD/C) studyHarikrishna Tandri, Robson Macedo, Hugh Calkins, et al.Cardiovascular Diabetology|June 23, 2021
Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trialGregory G Schwartz, Stephen J Nicholls, Peter P Toth, et al.Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 10, 2022
Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulatorsLaura M Tsujikawa, Olesya A Kharenko, Stephanie C Stotz, et al.Cardiovascular Therapeutics|August 22, 2020
Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular DiseaseSylwia Wasiak, Dean Gilham, Emily Daze, et al.Pageof 13